Biogen Technical Analysis



As of date:3/28/2024
BIIB stock price:215.63
BIIB 50 DMA:229.64
BIIB 200 DMA:251.96
BIIB MACD (200-50):22.32
BIIB RSI:39.22
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)39.22
Extremely
Oversold

Also see:
BIIB Market Cap History
BIIB Shares Outstanding History
BIIB YTD Return

Quotes delayed 20 minutes

Email EnvelopeFree BIIB Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

MasterCraft Boat Holdings (MCFT) Shares Cross Above 200 DMA
25 minutes ago


Fox Breaks Above 200-Day Moving Average - Bullish for FOXA
25 minutes ago


Vitru Breaks Above 200-Day Moving Average - Bullish for VTRU
25 minutes ago


SASR Makes Bullish Cross Above Critical Moving Average
1 hour, 22 minutes ago


MAG Makes Bullish Cross Above Critical Moving Average
1 hour, 29 minutes ago


Bullish Two Hundred Day Moving Average Cross - CRF
1 hour, 30 minutes ago


DoubleVerify Holdings Breaks Above 200-Day Moving Average - Bullish for DV
1 hour, 38 minutes ago


BIP Crosses Above Key Moving Average Level
1 hour, 45 minutes ago


ZROZ Makes Bullish Cross Above Critical Moving Average
1 hour, 47 minutes ago


Bullish Two Hundred Day Moving Average Cross - HAE
1 hour, 48 minutes ago


AES Shares Cross Above 200 DMA
1 hour, 48 minutes ago


SRE Crosses Above Key Moving Average Level
1 hour, 48 minutes ago


iShares iBonds Dec 2028 Term Muni Bond Getting Very Oversold
1 hour, 48 minutes ago


ZROZ Makes Bullish Cross Above Critical Moving Average
1 hour, 49 minutes ago


FN.CA Makes Bullish Cross Above Critical Moving Average
2 hours, 2 minutes ago


More Technical Analysis News

BIIB Technical AnalysisBIIB RSI
Biogen is a biopharmaceutical company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Co. has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Co. also commercialize biosimilars of biologics and focuses on improving its pipeline in neuroscience and immunology. Co.'s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis.

When researching a stock like Biogen, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from BIIB Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for BIIB stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
BIIB DMABIIB MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Biogen (BIIB) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

BIO Technical Analysis
BMY Technical Analysis
BSX Technical Analysis
CAH Technical Analysis
CI Technical Analysis
CNC Technical Analysis
COO Technical Analysis
COR Technical Analysis
CRL Technical Analysis
CTLT Technical Analysis
More Healthcare companies »

 

Biogen Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2024, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.